Health and Me on MSN1d
Yearly Jab For HIV Protection Is Now Almost HereA yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
2d
MedPage Today on MSNOnce-Yearly Lenacapavir PrEP a Safe, Promising Alternative to Twice-Yearly DosingA once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...
March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...
Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
An end-to-end digital PrEP pathway appeared to improve accessibility, inclusivity, and service satisfaction among LGBTQ+ ...
Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...
4d
News-Medical.Net on MSNGilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIVGilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
Children exposed to antiretroviral (ARV) therapy in utero and not exposed to HIV showed no difference in language development at 5 years of age compared with unexposed children, based on new data from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results